Searchable abstracts of presentations at key conferences in endocrinology

ea0056p837 | Pituitary - Clinical | ECE2018

Cushing’s disease with negative or inconclusive MRI: reassessment of transphenoidal surgery at the age of medical treatment. Post operative remission rate in 184 patients including 86 with negative or inconclusive MRI

Cristante Justine , Lefournier Virginie , Sturm Nathalie , Guy Passagia Jean , Gay Emmanuel , Chabre Olivier

When pituitary MRI show a typical imaging of adenoma, it is agreed that transsphenoidal surgery is the reference treatment with remission achieved in about 80% of patients. If MRI is negative or inconclusive, some authors consider that the results of surgery are less successful, and propose medical treatment as a first line therapy, despite a disease control rate between 30 and 70%. Since 1990, our center chose to systematically explore patients with ACTH dependent hypercortic...

ea0056p32 | Adrenal cortex (to include Cushing's) | ECE2018

How can cortisol-normalized adrenal venous sampling miss some Conn’s adenoma

Duparc Elea , Constantinescu Georgiana , Ormezzano Olivier , Thony Frederic , Rodiere Mathieu , Baguet Jean-Philippe , Gomez-Sanchez Celsio , Fernandes-Rosa Fabio , Sturm Nathalie , Chaffanjon Philippe , Chabre Olivier

Introduction: In patients with primary aldosteronism (PA) international consensus claim that adrenal venous sampling (AVS) performs better than CT scan in determining lateralization of aldosterone secretion. The SPARTACUS study has however reported similar performances for lateralization by CT scan and AVS in patients with PA and a unilateral adrenal mass. The standard procedure for AVS uses cortisol values to validate the selectivity of catheterization and to normalize the al...

ea0022p383 | Endocrine tumours &amp; neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience

Raverot Gerald , Sturm Nathalie , De Fraipont Florence , Caron Philippe , Muller Marie , Cortet-Rudelli Christine , Salenave Sylvie , Assaker Richard , Dufour Henry , Gaillard Stephan , Francois Patrick , Jouanneau Emmanuel , Bernier Michele , Figarella-Branger Dominique , Maurage Claude-Alain , Trouillas Jacqueline , Borson-Chazot Francoise , Brue Thierry

Context: To date ten publications reporting only 16 patients with pituitary aggressive tumors or carcinomas treated with temozolomide are available. Expression of O6-methylguanine-DNA-methyltranferase (MGMT), a DNA repair protein implicated in the resistance to temozolomide, was studied in only 10 out of these 16 patients. It has been suggested that low expression of MGMT could predict temozolomide efficacy.Objective: The aim of this st...